New Epidemiological Report: Santiago, Recoleta and Puente Alto lead communes with the largest number of new cases of Covid-19



[ad_1]

According to the new epidemiological report on Covid-19 released on Friday night by the Ministry of Health, the communes of Santiago, Recoleta, Puente Alto They lead the list of communes that have registered the highest number of new infected compared to the report issued last Tuesday, May 5.

In the last 3 days, the commune of Santiago registered 372 new cases, reaching a total of 1,666. Recoleta follows, with 287 new infected, to reach 889. For its part, Puente Alto added 275 positive cases in the period, giving a total of 1,404 affected.

They are followed by the communes of La Florida, with 246 new cases; Independencia, with 242: Quilicura, with 212; Peñalolén, with 166; Las Condes, with 149; San Bernardo, with 139, and La Pintana and Maipú, both with 138 new cases.

As for percentage of increase, the commune of Iquique it doubled its cases, going from 122 to 253, or an increase of 107.4%. While, Valparaiso it rose 55.1%, from 109 to 169 infected.

While Hill, with 51.3%; Macul, with 50.3%; San Ramon, with 48.6; Saint Joaquin, with 47.9%, and Recoleta, with 47.7%, reach the most significant percentage increases in the Metropolitan Region.

Regarding the total number of cases, 11 communes of the RM have more than 500 total cases and 24 others register more than 300. Only six other communes in the country present more than 300 cases, including Punta Arenas (825), Temuco (711), Antofagasta (601), Chillán (418), Arica (328) and Osorno (320).

The Minsal report indicates that in the country, until May 7, 25,972 cases of Covid-19 have been confirmed per laboratory, with a cumulative incidence rate of 133.5 per 100,000 inhabitants.

The highest cumulative incidence rates per 100,000 inhabitants, according to laboratory-confirmed cases, are found in the regions of Magallanes (486.1), Metropolitana (221.3), Ñuble (155.2) and La Araucanía (138.3), all above the observed national rate.

Of the confirmed cases, and reported on the Epivigila platform, the median age is 38 years, where 5.5% corresponded to children under 15 years of age; 23.9% to people between 15 and 29 years old; 32.8% to people between 30 and 44 years old; 27.7% to people aged 45-64 years, while the remaining 10.1% to adults 65 and over.



[ad_2]